GlassScriptPhysician profile
Manjul D Derasari
NPI 1912969775
$1,957.08
in general payments reported to CMS, 2019-2025
28 companies · $358 in 2025
The $358 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $142 · 2021: $315 · 2022: $207 · 2023: $407 · 2024: $169 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $334.57 | 2021-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Synchromedii |
| Boston Scientific Corporation | $270.39 | 2021-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Scilex Pharmaceuticals INC. | $157.18 | 2019-2023 | Ztlido |
| Collegium Pharmaceutical, INC. | $149.68 | 2019-2022 | |
| Amgen INC. | $123.77 | 2019 | |
| Medtronic USA, INC. | $99.28 | 2019-2020 | |
| Si-Bone, INC. | $96.96 | 2024-2025 | |
| Abbott Laboratories | $88.09 | 2023-2025 | Proclaim, Ionicrf |
| Nevro Corp. | $84.63 | 2019-2023 | Senza |
| Protega Pharmaceutials INC | $78.98 | 2022-2025 | Roxybond |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.24 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $53.05 | 2021 | |
| Almatica Pharma LLC | $51.11 | 2021-2023 | Gralise |
| Elutia, INC. | $30.33 | 2023 | |
| Fidia Pharma USA INC. | $28.30 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $23.45 | 2022 | |
| Averitas Pharma INC. | $22.25 | 2025 | Qutenza |
| Coastal Medical Technologies LLC | $21.97 | 2025 | |
| Globus Medical, INC. | $21.29 | 2025 | Senza |
| Abbvie INC. | $21.23 | 2025 | |
| Curonix LLC | $20.21 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Indivior INC. | $18.31 | 2019 | |
| Spr Therapeutics, INC | $16.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.94 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $14.72 | 2023 | Iovera, Zilretta |
| Avanos Medical | $14.47 | 2021 | |
| Pfizer INC. | $14.01 | 2019 | |
| Bioventus LLC | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manjul Derasari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.